SRGN and cancer: Taken together, these findings suggested that tumor cell surface receptor CD44 plays an important role in responding to tumor microenvironment-associated ligands, including SRGN, to potentiate cancer cell aggressiveness via triggering cytoskeleton remodeling and pro-survival pathway.